New Age Alpha Advisors LLC Cuts Stake in IQVIA Holdings Inc. $IQV

New Age Alpha Advisors LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 26.3% during the 4th quarter, HoldingsChannel reports. The firm owned 13,325 shares of the medical research company’s stock after selling 4,745 shares during the quarter. New Age Alpha Advisors LLC’s holdings in IQVIA were worth $3,004,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Claret Asset Management Corp raised its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after buying an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after buying an additional 58 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the last quarter. Brookstone Capital Management raised its holdings in shares of IQVIA by 2.2% during the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after buying an additional 63 shares during the last quarter. Finally, Keybank National Association OH raised its holdings in shares of IQVIA by 0.7% during the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $161.94 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $136.41 and a 12 month high of $247.04. The stock has a market cap of $27.03 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.61 and a beta of 1.18. The stock’s 50 day moving average price is $169.78 and its 200 day moving average price is $196.80. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the company earned $2.70 earnings per share. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IQV. Citigroup cut their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Evercore reaffirmed an “outperform” rating and set a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Truist Financial cut their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Buy” and a consensus price target of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.